Korean firm introduces new botulinum toxin for aesthetics market
An unique license to register, market and market a botulinum toxin (DTX-021) in america and Canada
Aquavit Holdings LLC, along with its manufacturing associate Huons Bio Pharma, introduced that it has acquired an unique license to register, market and commercialize a botulinum toxin (DTX-021) in United States and Canada.
Huons Bio Pharma, a spin-off of South Korean listed firm Huons International, will obtain important milestone funds and royalties along with an upfront fee and turn out to be the unique botulinum toxin provider to Aquavit. Aquavit plans to provoke the registration course of shortly by submitting an IND with the FDA.
In keeping with an article revealed by the American Society for Dermatologic Surgical procedure (ASDS), the licensed energetic DTX-021 confirmed equivalence on glabellar strains and enchancment in periorbital rhytids in comparison with onabotulinumtoxinA (BOTOX®) in a multicenter, double-blind, randomized, parallel, active-controlled section III scientific trial. There have been no antagonistic occasions.
In keeping with The Aesthetic Society and International Market Insights, botulinum toxin has been the # 1 non-surgical beauty process since 1999 and continues to develop quickly.
Botulinum toxin (Botox) is a neurotoxic protein produced by the bacterium Clostridium botulinum and associated species. It prevents the discharge of the neurotransmitter acetylcholine from axonal endings on the neuromuscular junction, thus inflicting flaccid paralysis.